$KLTO
Stock $klto

$klto Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000121390024046038 Filed on May 23, 2024

Income Statement

Concept	2024 Q1	2023 Q4
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$342.8K	$324.9K
YoY Change	5.23%	35.64%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$342.8K	$324.9K
YoY Change	5.23%	35.64%
Operating Profit	-$342.8K
YoY Change	5.23%
Interest Expense	$251.7K	$509.9K
YoY Change	-85.31%	-54.43%
% of Operating Profit
Other Income/Expense, Net	$16.96K	$15.90K
YoY Change	-260.0%
Pretax Income	-$74.15K	$200.9K
YoY Change	-105.39%	-77.15%
Income Tax	$49.07K	$112.0K
% Of Pretax Income		55.75%
Net Earnings	-$123.2K	$88.92K
YoY Change	-111.0%	-87.58%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.02	$0.01
COMMON SHARES
Basic Shares Outstanding		8.802M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.050K	$172.5K
YoY Change	-93.18%	-49.4%
Cash & Equivalents	$8.051K	$172.5K
Short-Term Investments
Other Short-Term Assets		$27.00K
YoY Change		-72.78%
Inventory
Prepaid Expenses		$27.00K
Receivables
Other Receivables
Total Short-Term Assets	$8.051K	$199.5K
YoY Change	-97.63%	-54.67%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$19.58M	$19.26M
YoY Change	-83.61%	-83.65%
Other Assets		$2.186M
YoY Change
Total Long-Term Assets	$19.58M	$19.26M
YoY Change	-83.61%	-83.65%
TOTAL ASSETS
Total Short-Term Assets	$8.051K	$199.5K
Total Long-Term Assets	$19.58M	$19.26M
Total Assets	$19.59M	$19.46M
YoY Change	-83.65%	-83.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$151.3K
YoY Change
Accrued Expenses	$1.586M	$1.497M
YoY Change	417.0%	966.13%
Deferred Revenue
YoY Change
Short-Term Debt	$347.1K	$65.00K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.583M	$2.313M
YoY Change	-96.0%	356.91%
LONG-TERM LIABILITIES
Long-Term Debt	$1.540M	$1.540M
YoY Change	3153.75%
Other Long-Term Liabilities	$4.354M	$4.371M
YoY Change	-0.02%	0.61%
Total Long-Term Liabilities	$5.894M	$5.911M
YoY Change	33.88%	36.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.583M	$2.313M
Total Long-Term Liabilities	$5.894M	$5.911M
Total Liabilities	$8.495M	$8.242M
YoY Change	-87.71%	67.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$7.729M	-$7.351M
YoY Change	58.43%	81.73%
Common Stock	$340.00	$340.00
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.728M	$11.21M
YoY Change
Total Liabilities & Shareholders Equity	$19.59M	$19.46M
YoY Change	-83.65%	-83.55%

Cashflow Statement

Concept	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$123.2K	$88.92K
YoY Change	-111.0%	-87.58%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$376.5K	-$248.8K
YoY Change	0.95%	239.98%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$70.00K	$39.07M
YoY Change	-80.56%
Cash From Investing Activities	-$70.00K	$39.07M
YoY Change	-80.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$282.1K	-38.79M
YoY Change	-44.7%
NET CHANGE
Cash From Operating Activities	-$376.5K	-248.8K
Cash From Investing Activities	-$70.00K	39.07M
Cash From Financing Activities	$282.1K	-38.79M
Net Change In Cash	-$164.5K	26.20K
YoY Change	-26.23%	-135.8%
FREE CASH FLOW
Cash From Operating Activities	-$376.5K	-$248.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-41340
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	Redwoods Acquisition Corp.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2727441
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1115 Broadway
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	12th Floor
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10010
CY2024Q1	dei	City Area Code CityAreaCode	(646)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	916-5315
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	true
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5165194	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8051	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	172535	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	26995	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	8051	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	199530	usd
CY2024Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	19578086	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	19256423	usd
CY2024Q1	us-gaap	Assets Assets	19586137	usd
CY2023Q4	us-gaap	Assets Assets	19455953	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	467916	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	396669	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	347052	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	65000	usd
CY2024Q1	rwod	Franchise Tax Payable Current FranchiseTaxPayableCurrent	93600	usd
CY2023Q4	rwod	Franchise Tax Payable Current FranchiseTaxPayableCurrent	75600	usd
CY2024Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	650462	usd
CY2023Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	751562	usd
CY2024Q1	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	1024249	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	1024249	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2583279	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2313080	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	41340	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	58300	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	18087	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	17919	usd
CY2024Q1	rwod	Deferred Underwriting Fee Payables DeferredUnderwritingFeePayables	4312500	usd
CY2023Q4	rwod	Deferred Underwriting Fee Payables DeferredUnderwritingFeePayables	4312500	usd
CY2024Q1	us-gaap	Liabilities Liabilities	8495206	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8241799	usd
CY2024Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	1760194	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	1760194	shares
CY2024Q1	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.69
CY2023Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.55
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	18819250	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	18564656	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3405000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3405000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3405000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3405000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	340	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	340	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7728659	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7350842	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-7728319	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7350502	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19586137	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19455953	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	324777	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	293654	usd
CY2024Q1	rwod	Franchise Tax Expenses FranchiseTaxExpenses	18000	usd
CY2023Q1	rwod	Franchise Tax Expenses FranchiseTaxExpenses	32100	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-342777	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-325754	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	251663	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1250068	usd
CY2023Q1	rwod	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-462670	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-16960	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10600	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-74154	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1376384	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	49069	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	255773	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-123223	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1120611	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7350502	usd
CY2024Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	254594	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-123223	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-7728319	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4044512	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1322195	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	631696	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1120611	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4877792	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-123223	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1120611	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	251663	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1250068	usd
CY2023Q1	rwod	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-462670	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-16960	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10600	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-26995	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	122876	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	71247	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	166354	usd
CY2024Q1	rwod	Increase Decrease Franchise Tax Payable IncreaseDecreaseFranchiseTaxPayable	18000	usd
CY2023Q1	rwod	Increase Decrease Franchise Tax Payable IncreaseDecreaseFranchiseTaxPayable	-90701	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-101100	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	160947	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-168	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-94826	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-376536	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-372977	usd
CY2024Q1	rwod	Cash Deposited In Trust Account CashDepositedInTrustAccount	-70000	usd
CY2023Q1	rwod	Cash Deposited In Trust Account CashDepositedInTrustAccount	-360000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-360000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	510000	usd
CY2024Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	282052	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	282052	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	510000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-164483	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-222977	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	172535	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	340962	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8051	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117985	usd
CY2024Q1	rwod	Net Loss Including Accretion Of Common Stock To Redemption Value NetLossIncludingAccretionOfCommonStockToRedemptionValue	254594	usd
CY2023Q1	rwod	Net Loss Including Accretion Of Common Stock To Redemption Value NetLossIncludingAccretionOfCommonStockToRedemptionValue	1322195	usd
CY2023Q1	rwod	Exercise Taxliability ExerciseTaxliability	631696	usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	150000	usd
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2022Q2	rwod	Total Gross Proceeds TotalGrossProceeds	4775000	usd
CY2024Q1	rwod	Units Issued During Period Shares New Issues UnitsIssuedDuringPeriodSharesNewIssues	1500000	shares
CY2022Q2	rwod	Purchased Public Units PurchasedPublicUnits	1500000	shares
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2022Q2	rwod	Total Gross Proceeds TotalGrossProceeds	525000	usd
CY2024Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	8365339	usd
CY2024Q1	rwod	Underwriting Fees UnderwritingFees	2875000	usd
CY2024Q1	rwod	Deferred Underwriting Fees DeferredUnderwritingFees	4312500	usd
CY2024Q1	rwod	Other Offering Costs OtherOfferingCosts	1177839	usd
CY2022Q2	rwod	Total Amount TotalAmount	116150000	usd
CY2024Q1	rwod	Aggregate Of Shares AggregateOfShares	6103350	shares
CY2024Q1	rwod	Redemption Value RedemptionValue	63169451	usd
CY2024Q1	rwod	Redemption Per Share RedemptionPerShare	10.35
CY2024Q1	rwod	Initial Threemonth Extension InitialThreemonthExtension	360000	usd
CY2024Q1	rwod	Onemonth Extension OnemonthExtension	120000	usd
CY2023Q4	rwod	Trust Account Amount TrustAccountAmount	120000	usd
CY2023Q4	rwod	Trust Account Amount TrustAccountAmount	35000	usd
CY2023Q4	rwod	Aggregate Shares AggregateShares	3636456	shares
CY2023Q4	rwod	Redemption Value Per Share RedemptionValuePerShare	10.79
CY2023Q4	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	35000	usd
CY2023Q4	us-gaap	Deposits Deposits	35000	usd
CY2024Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.1
CY2024Q1	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1	pure
CY2024Q1	us-gaap	Deposits Deposits	35000	usd
CY2024Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.1
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	60000000	usd
CY2024Q1	rwod	Description Of Contingent Consideration Shares DescriptionOfContingentConsiderationShares	(i) 2,000,000 Contingent Consideration Shares upon the Company achieving a closing price equal to or exceeding $12.50 for 10 trading days within a 20-day trading period in the first three years following the closing of the Merger; (ii) 2,000,000 Contingent Consideration Shares upon the Company achieving a closing price equal to or exceeding $15.00 for 10 trading days within a 20-day trading period in the first three years following the closing of the Merger; and (iii) 1,000,000 Contingent Consideration Shares upon the Company achieving a closing price equal to or exceeding $20.00 for 10 trading days within a 20-day trading period in the first five years following the closing of the Merger
CY2024Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	2875000	shares
CY2023Q2	rwod	Termination Date TerminationDate	2024-06-04
CY2023Q2	us-gaap	Interest Income Other InterestIncomeOther	519231	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	153089	usd
CY2023Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	150000	usd
CY2024Q1	us-gaap	Cash Cash	8051	usd
CY2024Q1	rwod	Working Capital Deficit WorkingCapitalDeficit	2575228	usd
CY2023Q1	rwod	Sponsor Provided Loan SponsorProvidedLoan	150000	usd
CY2023Q1	rwod	Sponsor Provided Loan SponsorProvidedLoan	360000	usd
CY2023Q2	rwod	Sponsor Provided Loan SponsorProvidedLoan	360000	usd
CY2023Q3	rwod	Sponsor Provided Loan SponsorProvidedLoan	150000	usd
CY2023Q3	rwod	Sponsor Provided Loan SponsorProvidedLoan	120000	usd
CY2023Q4	rwod	Sponsor Provided Loan SponsorProvidedLoan	400000	usd
CY2024Q2	us-gaap	Deposits Deposits	35000	usd
CY2022Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.01	pure
CY2022Q3	us-gaap	Reporting Unit Percentage Of Fair Value In Excess Of Carrying Amount ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount	0.01	pure
CY2024Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1024250	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing these consolidated financial statements in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8051	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	172535	usd
CY2024Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	8365339	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.6617	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.1858	pure
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-123223	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1120611	usd
CY2024Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	254594	usd
CY2023Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1322195	usd
CY2024Q1	rwod	Net Loss Including Accretion Of Common Stock Redemption Value NetLossIncludingAccretionOfCommonStockRedemptionValue	-377817	usd
CY2023Q1	rwod	Net Loss Including Accretion Of Common Stock Redemption Value NetLossIncludingAccretionOfCommonStockRedemptionValue	-201584	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution and money market funds held in the Trust Account. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2024Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	19578086	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	19256423	usd
CY2024Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	19578086	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	19256423	usd
CY2024Q1	us-gaap	Other Additional Capital OtherAdditionalCapital	1500000	usd
CY2024Q1	us-gaap	Long Term Debt Term LongTermDebtTerm	P5Y
CY2024Q1	us-gaap	Partners Capital Account Units Sold In Public Offering PartnersCapitalAccountUnitsSoldInPublicOffering	11500000	shares
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	115000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	10695000	usd
CY2022Q4	rwod	Proceeds Allocated To Public Rights ProceedsAllocatedToPublicRights	-9430000	usd
CY2022Q4	rwod	Offering Costs Of Public Shares OfferingCostsOfPublicShares	-6901405	usd
CY2022	rwod	Accretion Of Class A Ordinary Shares To Accreted Value AccretionOfClassAOrdinarySharesToAccretedValue	29388057	usd
CY2022Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	117361652	usd
CY2023	rwod	Accretion Of Class A Ordinary Shares To Accreted Value AccretionOfClassAOrdinarySharesToAccretedValue	3627865	usd
CY2023	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	102424861	usd
CY2023Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	18564656	usd
CY2024Q1	rwod	Accretion Of Class A Ordinary Shares To Accreted Value AccretionOfClassAOrdinarySharesToAccretedValue	254594	usd
CY2024Q1	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	18819250	usd
CY2024Q1	rwod	Aggregate Private Units AggregatePrivateUnits	477500	shares
CY2024Q1	rwod	Sale Of Stock Price Per Shares SaleOfStockPricePerShares	10
CY2024Q1	rwod	Aggregate Purchase Price AggregatePurchasePrice	4775000	usd
CY2024Q1	rwod	Additional Aggregates Private Units AdditionalAggregatesPrivateUnits	52500	shares
CY2024Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	525000	usd
CY2023Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	150000	usd
CY2023Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	360000	usd
CY2023Q3	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	150000	usd
CY2024Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	1540000	usd
CY2023	rwod	Accrued Expenses AccruedExpenses	3	usd
CY2024Q1	rwod	Accrued Expenses AccruedExpenses	30000	usd
CY2023Q1	rwod	Accrued Expenses AccruedExpenses	30000	usd
CY2024Q1	us-gaap	Interest Costs Incurred InterestCostsIncurred	240000	usd
CY2023	us-gaap	Interest Costs Incurred InterestCostsIncurred	210000	usd
CY2024Q1	rwod	Underwriting Discount Percentage UnderwritingDiscountPercentage	0.025	pure
CY2024Q1	rwod	Generating Gross Proceeds GeneratingGrossProceeds	2875000	usd
CY2024Q1	rwod	Deferred Fee DeferredFee	0.0375	pure
CY2024Q1	us-gaap	Purchase Options Land PurchaseOptionsLand	100	usd
CY2024Q1	rwod	Unit Purchase Option UnitPurchaseOption	345000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.5
CY2024Q1	rwod	Aggregate Exercise Price AggregateExercisePrice	3967500	usd
CY2024Q1	us-gaap	Line Of Credit Facility Expiration Period LineOfCreditFacilityExpirationPeriod	P5Y
CY2024Q1	us-gaap	Dividends Share Based Compensation Cash DividendsShareBasedCompensationCash	100	usd
CY2024Q1	rwod	Right Of First Refusal Description RightOfFirstRefusalDescription	The Company has granted Chardan a right of first refusal, for a period of 18 months after the date of the consummation of a Business Combination, to act as a book-running manager or placement agent, with at least 30% of the economics, for any and all future public and private equity, equity linked and debt offerings of the Company or any of its successors or subsidiaries.
CY2024Q1	us-gaap	Debtor Reorganization Items Legal And Advisory Professional Fees DebtorReorganizationItemsLegalAndAdvisoryProfessionalFees	200000	usd
CY2024Q1	us-gaap	Legal Fees LegalFees	500000	usd
CY2024Q1	rwod	Deferred Legal Fees Service DeferredLegalFeesService	1500000	shares
CY2023	rwod	Deferred Legal Fees Service DeferredLegalFeesService	1200000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3405000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3405000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3405000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3405000	shares
CY2024Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	1760194	shares
CY2024Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	11500000	shares
CY2024Q1	rwod	Market Price Percentage MarketPricePercentage	1.15	pure
CY2024Q1	rwod	Redemption Price Per Share RedemptionPricePerShare	16.5
CY2024Q1	rwod	Market Valuein Percentage MarketValueinPercentage	1.65	pure
CY2024Q1	rwod	Price Per Warrant PricePerWarrant	0.01
CY2024Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	16.5
CY2024Q1	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	41340	usd
CY2023Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	58300	usd
CY2022Q2	rwod	Fair Value Of Private Warrants FairValueOfPrivateWarrants	587717	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2024Q1	rwod	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Underlying Share Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsUnderlyingSharePrice	11.97
CY2023Q4	rwod	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Underlying Share Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsUnderlyingSharePrice	10.7
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.054	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.0351	pure
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0421	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0384	pure
CY2024Q1	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	5
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2024Q1	rwod	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes		usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2024Q1	rwod	Exercise Taxliability ExerciseTaxliability		usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2024Q1	us-gaap	Long Term Debt Term LongTermDebtTerm	P5Y
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001907223

Files In Submission

Name	View Source	Status
0001213900-24-046038-index-headers.html	Edgar Link	pending
0001213900-24-046038-index.html	Edgar Link	pending
0001213900-24-046038.txt	Edgar Link	pending
0001213900-24-046038-xbrl.zip	Edgar Link	pending
ea0205875-10q_redwoods.htm	Edgar Link	pending
ea020587501ex31-1_redwood.htm	Edgar Link	pending
ea020587501ex31-2_redwood.htm	Edgar Link	pending
ea020587501ex32-1_redwood.htm	Edgar Link	pending
ea020587501ex32-2_redwood.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
ea0205875-10q_redwoods_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rwod-20240331.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
rwod-20240331_cal.xml	Edgar Link	unprocessable
rwod-20240331_lab.xml	Edgar Link	unprocessable
rwod-20240331_def.xml	Edgar Link	unprocessable
rwod-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KLTO
Stock $klto

2024 Q1 Form 10-Q Financial Statement

#000121390024046038 Filed on May 23, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KLTO Stock $klto

2024 Q1 Form 10-Q Financial Statement

#000121390024046038 Filed on May 23, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KLTO
Stock $klto